HealthDay News — A combination of fluticasone furoate and vilanterol reduces the rate of moderate or severe exacerbations among patients with chronic obstructive pulmonary disease (COPD), according to ...

Study authors performed a post hoc pooled analysis of data from 10 trials to assess the safety and efficacy of umeclidinium/vilanterol in elderly symptomatic patients with COPD.

There are hardly any evaluable data for patients with moderate COPD severity and for patients with few exacerbations; for higher severity grades with more exacerbations, evaluable data are lacking ...

The US Food and Drug Administration (FDA) today approved umeclidinium and vilanterol powder for inhalation (Anoro Ellipta, GlaxoSmithKline (GSK)/Theravance). The drug is the first combo bronchodilator ...

Treatment with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) triple therapy appears to be more efficacious in reducing ...

Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA? Treatment with once-daily single-inhaler fluticasone ...

Please provide your email address to receive an email when new articles are posted on . Improvements observed with triple therapy with umeclidinium, fluticasone furoate and vilanterol, and use of a ...

Fluticasone furoate/vilanterol (FF/VI) improved FEV1 but did not improve morning peak expiratory flow in pediatric patients with uncontrolled asthma. Among pediatric patients with uncontrolled asthma, ...

The European Commission has cleared the combination of umeclidinium and vilanterol (Anoro, GlaxoSmithKline/Theravance) for once-daily maintenance treatment to relieve ...